Navigation Links
Misonix Announces New Sales Agency Agreement for Eastern Europe

FARMINGDALE, N.Y., March 3 /PRNewswire-FirstCall/ -- Misonix, Inc. (Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and worldwide for other acute health conditions, has entered into a new, two year, sales agency agreement with privately-held Advanced Oncology Systems ("AOS"), based in Wuppertal, Germany, for the representation of the Sonablate(R) SB500 High Intensity Focused Ultrasound ("HIFU") System, the SonaStar(TM) Ultrasonic Surgical Aspiration System, the BoneScalpel(TM) Ultrasonic Bone Cutting System, and the SonicOne Ultrasound Cleansing & Debridement System.

AOS has extensive experience with capital equipment sales, with special emphasis in cancer therapy and neurosurgery. The agreement provides AOS with the rights to sell in most Eastern European countries, with a primary focus in Hungary, Poland, Romania, Bulgaria, the Russian Federation, Ukraine, and Georgia. Sales will be consummated primarily through specialty distributors; however, in certain instances, direct to hospital sales are permitted. Minimum sales performance criteria for each product platform are stipulated in the agreement.

The Sonablate is a state of the art High Intensity Focused Ultrasound ("HIFU") instrument used for the trans-rectal ablation of tumors of the prostate gland. Characteristics of HIFU, when used for this purpose, are clinical outcomes similar to other treatment modalities, but with low instances of urinary incontinence and sexual impotence.

The SonaStar is used by Neuro and General Surgeons for quick and efficient removal of both hard and soft tumors while sparing most vessels. In addition, OsteoSculpt(TM) bone shaving technology can be employed with the SonaStar to safely remove osseous structures, thus providing access to the surgical site.

The BoneScalpel is a tissue specific osteotomy device capable of making precise cuts through bone and hard tissue while largely preserving delicate soft tissue structures. It offers the convenience and speed of a power instrument without the potential hazards associated with rotary sharps.

The SonicOne is an innovative, ultrasonic wound care system that offers tissue specific debridement and cleansing for effective removal of devitalized tissue and fibrin deposits while sparing viable cellular structures. The SonicOne establishes a new standard in advanced wound care and ensures progress towards patient healing.

"Misonix is excited about Advanced Oncology Systems joining our sales and distribution organization. We are quite familiar with AOS' past sales successes in Central and Eastern Europe," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "AOS' reputation speaks for itself with respect to successfully introducing technology driven medical devices to their markets. We are very pleased that they will be representing four of our product platforms to their well established distribution channels."

About Misonix:

Misonix, Inc. (Nasdaq: MSON) designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

    Misonix Contact:              Investor Relations Contact:
    Richard Zaremba               Cameron Associates, Inc.
    631-694-9555                  Kevin McGrath            212-245-4577

SOURCE Misonix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Misonix Announces New Distribution Agreement for Israel
2. Misonix Reports Earnings and Increased Revenues for the Three and Six Months Ended December 31, 2008
3. Misonix Schedules Second Quarter Fiscal Year 2009 Financial Results Conference Call; February 9, 2009 at 4:30 P.M. Eastern
4. Misonix Announces New HIFU Distribution Agreement for Italy
5. Misonix Announces Extension and Expansion of Distribution Agreement With Mentor Corporation
6. Misonix Reports First Quarter Fiscal Year 2009 Financial Results
7. Misonix Schedules First Quarter Fiscal Year 2009 Financial Results Conference Call; November 13, 2008 at 4:30 P.M. Eastern
8. Misonix Subsidiary, Sonora Medical Systems, Announces a Major Ultrasound Probe Study
9. Misonix To Present at The Rodman & Renshaw 10th Annual Healthcare Conference
10. Cambridge Healthtech Institute Announces Its Premiere Collaborative Innovation in Biomedicine Conference
11. Boston Scientific Announces Japanese Launch of Taxus(R) Liberte(R) Drug-Eluting Stent System
Post Your Comments:
(Date:6/26/2016)... ... ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a weight ... app plans to fix the two major problems leading the fitness industry today:, ... program , They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, ... work on several important health care topics including advance care planning, healthcare costs ...
(Date:6/25/2016)... ... , ... The temporary closing of Bruton Memorial Library on June 21 due to a possible ... often overlooked aspect of head lice: the parasite’s ability to live away from a human ... but a necessary one in the event that lice have simply gotten out of control. ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016 Research and Markets has ... Companion Diagnostic Tests" report to their offering. ... Diagnostics The World Market for Companion Diagnostics ... diagnostics. Market analysis in the report includes the following: ... Vitro Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
Breaking Medicine Technology: